₩268,500.00
-6000.00 (-2.19%)
KRW · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where 005930.KS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 2 observational
Held by 0 tracked-famous managers · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Samsung GEMS-H Device Training in Sub-Acute and Chronic StrokeNCT04285060Incidence of device related adverse eventsOpen-label · Other | Not applicable | Unknown status | Device: Samsung GEMS-H | Stroke, Chronic Stroke | 100 | Nov 2021 | 2021-09-27 |
| Effect of GEMS-H on Locomotor Function in AdultsNCT03962517Change in 10 Meter Walk Test-Self Selected Velocity (sec) from Baseline to Post-Training AssessmentRandomized · Single-masked · Treatment | Not applicable | Completed | Device: with Gait Enhancing and Motivating System-Hip (GEMS-H) · Other: without Gait Enhancing and Motivating System-Hip (GEMS-H) | Adults, Middle Age, Aged, Aged, 80 and Over | 70 | 2020-02-05actual | 2020-04-02 |
| Evaluation of the Samsung LABGEO IVD-A20 CHF Test in a Point-of-Care SettingNCT02107495observationalThe proportion of clinically-confirmed CHF subjects for whom the Samsung LABGEO IVD-A20 CHF Test result was positive (clinical sensitivity). | — | Terminatedsponsor's stated reason: Optimize calibration | Device: Samsung LABGEO IVD-A20 CHF Test | Congestive Heart Failure | 191 | Feb 2015actual | 2016-04-19 |
| Evaluation of the Samsung LABGEO PT10 Hepatic Panel in a Point-of-Care SettingNCT02104154observationalBias between Samsung LABGEO PT10 serum results and matching FDA-cleared comparator assay | — | Terminatedsponsor's stated reason: To conduct interim analysis and assess whether assay changes are recommended. | Device: Samsung LABGEO PT10 Hepatic Panel | Hepatic Disease | 32 | Sep 2014actual | 2015-02-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19